Search

Your search keyword '"Marc Perrussel"' showing total 7 results
Start Over Author "Marc Perrussel"
7 results on '"Marc Perrussel"'

2. Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study

Author

Bernhard Korge, Olivier Vanhooteghem, Charles W. Lynde, Alena Machovcova, Marc Perrussel, Elisavet Lazaridou, Claudio Marasca, David Vidal Sarro, Ines Duenas Pousa, Frederik Fierens, Paulette Williams, Saori Shimizu, Tanja Heidbrede, and Richard B. Warren

Subjects
Anti-TNF biologic, Certolizumab pegol, Dermatology life quality index (DLQI), Health-related quality of life, Moderate to severe psoriasis, Psoriasis area and severity index (PASI), Dermatology, RL1-803
Abstract

Abstract Introduction Certolizumab pegol (CZP) is an anti-tumor necrosis factor alpha (TNFα) approved for the treatment of moderate to severe plaque psoriasis (PSO). However, data on its real-world use is currently limited. The objective of this study was to describe the 1-year real-world effectiveness of CZP, its impact on health-related quality of life (HRQoL), and safety outcomes in patients with moderate to severe PSO in multi-country settings. Methods CIMREAL, a prospective, noninterventional study, was conducted across Europe and Canada from August 2019 to December 2022. Patients were followed for 1-year, receiving CZP 400 mg initial doses at weeks 0, 2, and 4, followed by CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg Q2W maintenance dosing. Effectiveness was assessed using the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI). Safety was also evaluated. Results Overall, 399 patients with moderate to severe PSO were included. Of these, 93.7% (374/399) and 77.9% (311/399) completed months 3 and 12, respectively. Mean age (± standard deviation) was 42.9 ± 13.5 years and body mass index was 28.5 ± 6.8 kg/m2, with the majority of patients being female (68.2%). At 12 months, CZP showed substantial effectiveness, achieving PASI 75 and PASI 90 response rates (≥ 75% and ≥ 90% improvement from baseline, respectively) of 77% and 56.5%, respectively. Patients with PASI score of ≤ 3 and ≤ 2 experienced improvement from 3 months (49.8% and 41.1%, respectively) to 12 months (82.0% and 75.3%, respectively). HRQoL considerably improved, with mean DLQI scores decreasing from 12.4 to 2.3 after 12 months of treatment, and the proportion of patients with DLQI 0/1 increased from 28.6% at 3 months to 59.4% at 12 months. The 1-year probability of persistence was approximately 85%. Overall, 30.6% of the patients experienced any adverse events and 9.3% had serious adverse events. Conclusion In routine clinical practice, CZP exhibited consistent effectiveness, positively impacting both skin psoriasis activity and HRQoL. The 1-year persistence of CZP was high, and no new safety signals were identified. Trial Registration Number ClinicalTrials.gov Identifier: NCT04053881 https://www.clinicaltrials.gov/study/NCT04053881 .

Published
2024
Full Text
View/download PDF

3. Calcipotriol/betamethasone foam for proactive management of plaque psoriasis: four case reports

Author

Zoe Apalla, Marc Perrussel, and Efstathios Rallis

Subjects
aerosol foam, betamethasone dipropionate, calcipotriol, psoriasis, Therapeutics. Pharmacology, RM1-950
Abstract

Psoriasis is a chronic inflammatory disease affecting about 100 million people worldwide. Around 80% of patients can be treated with topical agents, most commonly corticosteroids and vitamin D analogues. A topical foam formulation of calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) (Cal/BD foam; Enstilar®) is approved for the daily treatment of psoriasis for up to 4 weeks and twice-weekly thereafter as maintenance treatment (after initial 4-week treatment success). Long-term proactive maintenance with Cal/BD foam for plaque psoriasis has been shown to prolong the time to first relapse, reduce the number of relapses and increase days in remission in the PSO-LONG trial. Four case studies of proactive management with Cal/BD foam for the treatment of plaque psoriasis for up to 12 months from initial presentation are described. These case studies provide real-world evidence on the long-term effectiveness of proactive management with Cal/BD foam as well as the improvement and maintenance of health-related quality of life. Cal/BD foam was well tolerated.

Published
2022
Full Text
View/download PDF

4. Switching biologics in children with psoriasis: Results from the BiPe cohort

Author

Céline, Phan, Alain, Beauchet, Ziad, Reguiai, Maëlla, Severino-Freire, Juliette, Mazereeuw-Hautier, Anne-Claire, Bursztejn, Sébastien, Barbarot, Smaïl, Hadj-Rabia, Céline, Girard, Alice, Phan, Jean-Philippe, Lacour, Audrey, Lasek, Claire, Abasq, Emilie, Brenaut, Marc, Perrussel, Catherine, Droitcourt, Stéphanie, Mallet, Maryam, Piram, Anne-Claire, Fougerousse, Hugues, Barthélémy, Xavier, Balguérie, and Emmanuel, Mahé

Subjects
Adult, Biological Products, Adolescent, Adalimumab, Dermatology, Etanercept, Young Adult, Treatment Outcome, Pediatrics, Perinatology and Child Health, Humans, Psoriasis, Female, Ustekinumab, Child, Retrospective Studies
Abstract

There is currently little information on switching biologics in pediatric psoriasis.To evaluate the real-world clinical practice and safety of switching biologics in the "Biological Treatments for Pediatric Psoriasis" (BiPe) cohort.Data for all 134 patients included in the BiPe cohort were analyzed. A further evaluation of the subpopulation of patients who switched from a first-line biologic to a second-line biologic was then conducted. Drug survival rates were also compared between biologics given as first-line or second-line agents.Overall, 29 patients (female: 55%; mean age: 16.6 ± 3.0 years) switched between two biologics. Etanercept (ETN) was the first-line biologic used in 23 patients: 16 (69.6%) switched to adalimumab (ADA) and seven (30.4%) to ustekinumab (UST). Six patients received first-line ADA and switched to UST. Loss of efficacy (62.1%), primary inefficacy (20.7%), and parental choice (6.9%) were the main reasons for switching biologics. One (3.4%) of the switches was performed because of adverse events or intolerance. For UST and ADA, the 18-month drug survival rate did not differ according to whether the agent was given as a first-line or second-line biologic (UST: P = .24; ADA: P = .68). No significant differences in drug survival rates were observed between the three different switches (ADA to UST, ETN to ADA, and ETN to UST).Our study provided key insights into the real-life clinical practice of switching biologics in pediatric psoriasis patients. However, more information and guidance on switching biologics in pediatric psoriasis are needed to improve real-life practice and outcomes.

Published
2021
Full Text
View/download PDF

5. Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France

Author

Adèle de Masson, Jean-David Bouaziz, Luc Sulimovic, Charles Cassius, Marie Jachiet, Marius-Anton Ionescu, Michel Rybojad, Martine Bagot, Tu-Anh Duong, Dominique Denjean, Marie-Pierre Labarthe, Maud Bézier, Marie Risbourg, Geneviève Payan, Sabrina Alain, Frédéric Mathivon, Anny Cohen-Letessier, Delphine Kerob, Jean-Philippe Hellier, Christelle Comte, Fabielle Keller, Caroline Brue, Paul Lestang, Laurence Allanore, Eliane Pierkarski-Carp, Anne Amoric, Hervé Serpier, Philippe Pruvost, Fabien Guibal, Damien Giacchero, Elisa Funck-Brentano, Sandrine Sierra Fortuny, Isabelle Gallay, Agnès Zavarro, Caroline Bider-Valle, Sylvie Lagrange, Etty Grynberg, Florence Weill, Dominique Penso, Marie Gomel, Jean Schneider, Anne Larabelle, Philippe Bonhomme, Marie-Sophie Gautier, Jean Hatchuel, Imane Mourtada, Charlotte Fite, Catherine Oliveres-Ghouti, Elisabeth Domergue, Sabrina Fourcade-Roch, Sylvie Lecanu, Nathalie Sebban, Bruno Halioua, Anne Bellut, Fabienne Keller, Isabelle Baratte, Françoise Lejoyeux, Laurence Ollivaud, Georges Abirached, Marielle Burnouf, Beatrix Reynayd-Mendel, Jean-Noël Dauendorffer, Joëlle Sebaoun, Hervé Garrat, Marie-Martine Pomper, Anne-Marie Heudes, Isabelle Beaulieu, Hugues Cartier, Amélie Arsouze, Dominique Lons-Danic, Michèle Pelletier, Valérie Gallais, Valérie Piantade, Marlène Risbourg, Georges Reuter, Serge Dahan, Murielle Creusot, Abdallah Kolli, Isabelle Egasse-Broca, Jean-Luc Rigon, Pascale Sabban, Hélène Flacher, Benoît Jaillard, Pierre André, Dominique Debjoux, Elodie Poirier, Bénédicte Solyga, Marc Perrussel, Sabrina Makhloufi, Bertrand Margnier, Clotilde Huzar, Laetitia Vandame, Hortense Thelu, Anne-Claire Chollet, Frédérique Marchal, Michael Naouri, Marion Nadaud, Elodie Boissy, Abdelhamid Lameche, Charles Berdougo, Audrey Rolland, Marie-Laure Fléchet, Gabriel Colonna, Delphine Jouannet, Isabelle Berdah, Françoise Truchot, Isabelle Lavallée, Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)

Subjects
Adult, Male, medicine.medical_specialty, 2019-20 coronavirus outbreak, Adolescent, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Pneumonia, Viral, Dermatology, Article, Betacoronavirus, Young Adult, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Pandemic, medicine, Humans, Child, Chilblains, Pandemics, Aged, Retrospective Studies, Aged, 80 and over, 030203 arthritis & rheumatology, SARS-CoV-2, business.industry, COVID-19, Retrospective cohort study, Middle Aged, medicine.disease, Child, Preschool, Female, France, Coronavirus Infections, business
Published
2020
Full Text
View/download PDF

6. Psoriasis: characterization of six different clinical phenotypes

Author

Marc Perrussel, Nejib Doss, Julie Latreille, Christiane Guinot, Louis Dubertret, CENTRE DE RECHERCHES ET D'INVESTIGATIONS EPIDERMIQUES ET SENSORIELLES (CERIES), CERIES, Université de Tours (UT), Centre d'enseignement Cnam Paris (CNAM Paris), Conservatoire National des Arts et Métiers [CNAM] (CNAM), Department of Dermatology, Military Hospital of Tunis, Service de dermatologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Tours, and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)

Subjects
Adult, Male, medicine.medical_specialty, Multivariate analysis, [SDV]Life Sciences [q-bio], Dermatology, Bioinformatics, Biochemistry, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Psoriasis, Surveys and Questionnaires, Medicine, Cluster Analysis, Humans, Prospective Studies, Age of Onset, Clinical phenotype, Prospective cohort study, Molecular Biology, Disease entity, Models, Genetic, business.industry, Middle Aged, medicine.disease, Phenotype, 3. Good health, 030220 oncology & carcinogenesis, Multivariate Analysis, Female, Age of onset, business
Abstract

International audience; Until recently, psoriasis was considered as a single disease entity. However, the discovery of major differences between early- or late-onset psoriasis suggests the presence of distinct disease phenotypes which may differ in their pathophysiology and in their treatment responsiveness. The objective of this study was to use exploratory data analysis methods to identify potential clinical psoriasis phenotypes without a priori hypotheses. A prospective questionnaire-based survey collected comprehensive informations on the main clinical characteristics of 1484 psoriatic patients. Six statistically different clusters of clinical symptoms were observed, corresponding at least to six different clinical psoriasis phenotypes. Moreover, discriminant functions allow patients to be assigned to one or other of these phenotypes. Our findings open the way to focus genetic, pharmaco-genetic, pathophysiological and therapeutic studies on more homogenous group of patients.

Published
2009
Full Text
View/download PDF

7. Hailey-Hailey disease is caused by mutations in ATP2C1 encoding a novel Ca(2+) pump

Author

Carol Dobson-Stone, Jacqueline K. White, Marc Perrussel, Eugene Healy, Tom Strachan, Alain Hovnanian, Juliane Ramser, Anthony P. Monaco, Hans Lehrach, Joanna Brown, Marc Larrègue, Ralf Sudbrak, S. Carter, Colin S. Munro, M.A.K.L. Dissanayake, and Susan Burge

Subjects
Genetic Markers, Keratinocytes, DNA, Complementary, Positional cloning, Genotype, Pemphigus, Benign Familial, Molecular Sequence Data, Calcium-Transporting ATPases, Biology, Gene mapping, Genetic linkage, Genetics, medicine, Cell Adhesion, Missense mutation, Humans, Keratosis follicularis, Amino Acid Sequence, Molecular Biology, Genetics (clinical), In Situ Hybridization, Fluorescence, Recombination, Genetic, Splice site mutation, Acantholysis, General Medicine, Exons, medicine.disease, Physical Chromosome Mapping, Molecular biology, Introns, Pedigree, Hailey–Hailey disease, Mutation, Chromosomes, Human, Pair 3
Abstract

Hailey-Hailey disease (HHD) is an autosomal dominant skin disorder characterized by suprabasal cell separation (acantholysis) of the epidermis. Previous genetic linkage studies localized the gene to a 5 cM interval on human chromosome 3q21. After reducing the disease critical region to

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results